肺移植は、肺の様々な疾患において使用される治療法です。肺移植とは、損傷や罹患した肺を健康なものと取り替える手術です。肺移植に関連したリスク要因として、出血、感染症、血栓、循環器疾患などがあります。移植後、免疫システムが移植された肺を異物とみなして攻撃することがあります。そのため、患者は合併症を発症し、最終的には新しい臓器を拒絶してしまいます。免疫抑制薬を同時に投与し、体が様々な免疫反応によって外部から来た臓器を同定あるいは攻撃するのを防ぎます。それによって臓器の拒絶反応を遮断し、移植の成功を促します。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lung Transplant Rejection - Overview
Lung Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Lung Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Lung Transplant Rejection - Companies Involved in Therapeutics Development
Amgen Inc
Apeptico Forschung und Entwicklung GmbH
Bristol-Myers Squibb Co
Isopogen Pty Ltd
Kamada Pharmaceuticals
MimeTech Srl
Radikal Therapeutics Inc
TFF Pharmaceuticals Inc
Veloxis Pharmaceuticals AS
Lung Transplant Rejection - Drug Profiles
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
History of Events
belatacept - Drug Profile
Product Description
Mechanism Of Action
History of Events
carfilzomib - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-554 - Drug Profile
Product Description
Mechanism Of Action
History of Events
R-801 - Drug Profile
Product Description
Mechanism Of Action
History of Events
solnatide - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Lung Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
History of Events
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
History of Events
tacrolimus ER - Drug Profile
Product Description
Mechanism Of Action
History of Events
udonitrectag - Drug Profile
Product Description
Mechanism Of Action
History of Events
Lung Transplant Rejection - Dormant Projects
Lung Transplant Rejection - Product Development Milestones
Featured News & Press Releases
Sep 23, 2021: TFF Pharmaceuticals announces promising topline results from phase 1 clinical trial of inhaled tacrolimus powder and progression toward phase 2 in lung transplantation
Jul 13, 2021: TFF Pharmaceuticals announces completion of enrollment and preliminary data from its phase 1 clinical trial of Tacrolimus Inhalation Powder
Jun 07, 2021: TFF Pharmaceuticals hosting key opinion leader perspectives on thin film freezing applications
Oct 20, 2020: TFF Pharmaceuticals updates progress of human clinical trial with tacrolimus inhalation powder
Jun 29, 2020: TFF Pharmaceuticals announces first human dosing with Tacrolimus inhalation powder
Jun 18, 2020: TFF Pharmaceuticals receives orphan drug designation for Tacrolimus inhalation powder
Oct 18, 2019: New insights into Alpha-1 Deficiency: A special scientific meeting organized by Kamada during the recent ERS congress
Feb 06, 2019: Kamada announces additional interim results from phase 2 proof of concept clinical trial of intravenous Alpha-1 Antitrypsin treatment for prevention of Lung Transplant Rejection
Jan 08, 2018: Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection
Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
Oct 05, 2015: APEPTICO receives Orphan Drug Designation by European Medicines Agency
Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection
Mar 03, 2015: APEPTICO provides update on phase IIa study of AP301 product candidate
Jul 08, 2013: APEPTICO receives research grant from Austrian Research Promotion Agency (FFG)
Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Lung Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Lung Transplant Rejection - Pipeline by Amgen Inc, 2022
Lung Transplant Rejection - Pipeline by Apeptico Forschung und Entwicklung GmbH, 2022
Lung Transplant Rejection - Pipeline by Bristol-Myers Squibb Co, 2022
Lung Transplant Rejection - Pipeline by Isopogen Pty Ltd, 2022
Lung Transplant Rejection - Pipeline by Kamada Pharmaceuticals, 2022
Lung Transplant Rejection - Pipeline by MimeTech Srl, 2022
Lung Transplant Rejection - Pipeline by Radikal Therapeutics Inc, 2022
Lung Transplant Rejection - Pipeline by TFF Pharmaceuticals Inc, 2022
Lung Transplant Rejection - Pipeline by Veloxis Pharmaceuticals AS, 2022
Lung Transplant Rejection - Dormant Projects, 2022
Lung Transplant Rejection - Dormant Projects, 2022 (Contd..1)
List of Figures
Number of Products under Development for Lung Transplant Rejection, 2022
Number of Products under Development by Companies, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Top 10 Routes of Administration, 2022
Number of Products by Stage and Top 10 Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022
